Ignite Creation Date:
2024-05-05 @ 10:17 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006327
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
2000-10-02
Brief Title:
Effectiveness of AIDSVAX BE Vaccine in Intravenous Drug Users in Bangkok Thailand
Sponsor:
VaxGen
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Trial to Determine the Efficacy of AIDSVAX BE Vaccine in Intravenous Drug Users in Bangkok Thailand
Status:
COMPLETED
Status Verified Date:
2003-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the vaccine AIDSVAX BE will protect intravenous drug users from becoming infected with HIV
Detailed Description:
Volunteers are immunized and followed for a minimum of 2 years Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months Behavior effects associated with study participation are assessed
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: